Modality
ADC
MOA
SGLT2i
Target
CDK4/6
Pathway
Angiogenesis
IPF
Development Pipeline
Preclinical
~Sep 2019
→ ~Dec 2020
Phase 1
Mar 2021
→ Jul 2029
Phase 1Current
NCT08638159
1,057 pts·IPF
2021-03→2029-07·Recruiting
1,057 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-07-233.3y awayPh2 Data· IPF
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1/2
Recruit…
Catalysts
Ph2 Data
2029-07-23 · 3.3y away
IPF
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08638159 | Phase 1/2 | IPF | Recruiting | 1057 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 |